Recombinant Human AICDA Protein，His

AICDA (Activation-Induced Cytidine Deaminase) is a crucial enzyme involved in the process of somatic hypermutation and class switch recombination in B cells, playing a vital role in the adaptive immune response. Research into AICDA has gained momentum due to its significance in maintaining the diversity of antibodies and its implications in immunological disorders. Dysregulated AICDA activity has been linked to various pathologies, including lymphomas and other cancers, as well as autoimmune diseases, highlighting the importance of understanding its regulatory mechanisms. The study of AICDA is further enhanced by the need to develop novel therapeutic interventions targeting B cell malignancies, where AICDA's aberrant function contributes to oncogenesis. Recent advances in recombinant protein technology have made it feasible to produce AICDA in substantial quantities, enabling detailed investigations into its structure-function relationships and enzymatic activity. By elucidating the biochemical and molecular mechanisms underpinning AICDA's actions, researchers aim to uncover potential targets for drug development and to design innovative treatments that could modulate immune responses or counteract the effects of AICDA in pathological contexts. Overall, the investigation of AICDA's role in immune regulation and disease susceptibility underscores its potential as a biomolecular target for therapeutic strategies in oncology and immunology.